Celgene — Biomedical Watch V2

Traitements5programmes

Essais3liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BMS-986368This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.	Alzheimer, Myopathies, SEP	Phase 2	À vérifier	United States, Australia, Canada, Czechia, Germany, Poland, Puerto Rico	À vérifier
Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line MonochemotherapyPost-authorization, prospective follow-up, multi-centre, national study to estimate definitive deterioration in the quality of life in patients with metastatic breast cancer treated with second-line monochemotherapy.	Cancer	À vérifier	À vérifier	Spain	À vérifier
Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line MonochemotherapyPost-authorization, prospective follow-up, multi-centre, national study to estimate definitive deterioration in the quality of life in patients with metastatic breast cancer treated with second-line monochemotherapy.	Cancer	À vérifier	À vérifier	Spain	À vérifier
BMS-986368This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.	Alzheimer	Phase 2	À vérifier	United States, Argentina, Australia, China	À vérifier
BMS-986368This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.	Myopathies	Phase 2	Traitement symptomatique	United States, Australia, Canada, Czechia, Germany, Poland, Puerto Rico	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
BMS-986368	Myopathies	Phase 2	NCT06782490	MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity	RECRUITING
BMS-986368	Alzheimer	Phase 2	NCT06808984	Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	RECRUITING
Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy	Cancer	À vérifier	NCT02403869	Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.